 Development systemic lupus erythematosus interferon therapy chronic myelogenous leukemia man Philadelphia-positive chronic myelogenous leukemia interferon-alpha IFN-alpha therapy months systemic lupus erythematosus disease features malar rash migratory arthralgias antinuclear antibodies antinative DNA hypocomplementemia lymphopenia proteinuria discontinuation IFN initiation corticosteroids gradual recovery symptoms decline antinative DNA antinuclear antibodies normal levels decrease proteinuria potential association IFN therapy development systemic lupus erythematosus role IFN autoimmune diseases